Drug Profile

INCB 161734

Alternative Names: INCB-161734

Latest Information Update: 15 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Incyte Corporation
Class Antineoplastics; Small molecules
Mechanism of Action KRAS protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Adenocarcinoma
Phase I Solid tumours

Most Recent Events

11 Sep 2026 Incyte Corporation plans phase I pharmacokinetics trial (In volunteers) in September 2026 (PO) (NCT07814404)
09 Apr 2026 Phase-III clinical trials in Adenocarcinoma (Combination therapy, First-line therapy, Metastatic disease) in USA, Puerto Rico (PO) (NCT07522073)
16 Mar 2026 Pharmacodynamics and advers evenet data from a preclinical trial in Solid tumour presented at the ESMO Targeted Anticancer Therapies Congress 2026 (TAT-2026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com